Is Passage BIO, Inc. (PASG) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 95.4% / 30% | 287.5% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 95.4% / 33% | 287.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 24.9% / 33% | 74.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 95.4% / 33% | 287.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 24.9% / 33% | 74.9% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -113.8% | |
| Return on Assets (ROA) | -32.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$32M |
| Free Cash Flow | -$32M |
| Total Debt | $24M |
| Debt-to-Equity | 128.0 |
| Current Ratio | 2.1 |
| Total Assets | $62M |
Price & Trading
| Last Close | $6.89 |
| 50-Day MA | $9.35 |
| 200-Day MA | $8.57 |
| Avg Volume | 58K |
| Beta | 1.8 |
|
52-Week Range
$5.12
| |
About Passage BIO, Inc. (PASG)
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Passage BIO, Inc. (PASG) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Passage BIO, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Passage BIO, Inc.'s debt ratio?
Passage BIO, Inc.'s debt ratio is 95.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 24.9%.
What are Passage BIO, Inc.'s key financial metrics?
Passage BIO, Inc. has a market capitalization of $20M. Return on equity stands at -113.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.